Thermo Fisher Scientific to Collaborate With University Hospital Basel on Companion Dx

Apr 18, 2017

|

NEW YORK (GenomeWeb) – Thermo Fisher Scientific has launched a program by which it will collaborate with partners to develop its next-generation sequencing-based Oncomine portfolio of products into clinical tests that can be used as companion diagnostics. The Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland will be the first partner in the initiative, dubbed the Next Generation Companion Dx Center of Excellence Program.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Mar

29

Featured Webinar

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar

31

Featured Webinar

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.

Apr

06

Featured Webinar

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.

Menu

Thermo Fisher Scientific to Collaborate With University Hospital Basel on Companion Dx

To read the full story....

Breaking News

Genetic Technologies Inks US Commercialization Deal for COVID-19 Risk Test With Infinity Biologix

Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

Agilent Prices $850M Senior Notes Offering

ClinSpec Diagnostics Raises $1.5M in Additional Funding

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Drug Screen Lab Owner Sentenced to 36 Months in Prison

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

What's Popular?

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding

Sponsorships